Quanterix Announces Publication Of Novel Method Expanding Single Molecule Detection Capability
Expansion of SiMoA Technology Will Enable Ultrasensitive Immunoassays with Broad Dynamic Range
Cambridge, MA – Quanterix Corporation, a single molecule diagnostics company providing technology with unprecedented sensitivity for the life science and in vitro diagnostics markets, today announced the online publication of a study that builds upon the company’s Single Molecule Array (SiMoA™) technology by combining digital and analog detection in one straightforward measurement. The article appears in the journal Analytical Chemistry, and highlights the ability to precisely measure proteins present at not only extremely low levels, but higher concentrations as well, effectively extending the dynamic range of immunoassays from the picomolar level down to sub-femtomolar levels in a single measurement.
“Many diagnostic applications require tests to be sensitive as well as perform over a broad spectrum of concentrations to allow target analytes to be measured in the majority of clinical samples. By combining the Quanterix digital approach for single molecule detection with ensemble measurements, we are able to measure proteins over a wider range than either method alone,” said David Duffy, Ph.D., corresponding author of the article.
David Okrongly, Ph.D., President and CEO of Quanterix added, “The ability to accurately measure proteins over a larger concentration range, down to sub-femtomolar levels, further moves the company towards our stated goal of providing a universal platform that will improve the quality and clinical value of immunodiagnostics. This expansion of our SiMoA technology allows us to deliver the most sensitive and precise results without sacrificing assay throughput or increasing cost in the clinical setting.”
Quanterix Corporation is developing its proprietary Single Molecule Array (SiMoA™) technology for the in vitro diagnostics and life science research markets. The digital nature of SiMoA yields unprecedented assay performance, stemming from a 1,000-fold improvement in sensitivity compared with today’s analog only technology. SiMoA will enable researchers in life science to validate novel, low abundance biomolecules from a single droplet of blood, leading to greater insight into disease detection, diagnosis, therapy selection and disease monitoring. Automated systems based on SiMoA will provide diagnostic test information to healthcare practitioners faster, with greater reliability, unprecedented range and increased cost effectiveness. Founded in 2007, the privately held Cambridge, Massachusetts-based company is backed by leading life science investors including ARCH Venture Partners, Bain Capital Ventures, and Flagship Ventures. For additional information, please visit www.quanterix.com.
Share this page